Skip to main content

Metabolism of (R)-[11C]verapamil in epilepsy patients

Introduction

(R)-[11C]Verapamil (VPM) is a new positron emission tomography (PET) tracer to measure P-glycoprotein (P-gp)-mediated transport at the blood-brain barrier (BBB). Owing to the lack of a suitable reference region in brain that is devoid of P-gp, a metabolite-corrected arterial input function is required for quantitative analysis of VPM PET data [1]. The aim of this study was to compare metabolism of VPM in epilepsy patients and healthy volunteers.

Methods

Selected arterial blood samples from 9 patients, who underwent VPM PET, were analyzed for radiolabeled metabolites by a previously described combined solid-phase extraction/HPLC assay [2].

Results

VPM metabolism was significantly faster in patients as compared to healthy volunteers [1] (unchanged VPM at 60 min after injection: 26.1 ± 6.4 vs. 49.0 ± 13.4%, p < 0.05, t-test).

Conclusion

Faster metabolism of VPM in epilepsy patients may be caused by CyP450 enzyme induction by antiepileptic drugs. Based on these data caution is warranted when using an averaged arterial input function derived from healthy volunteers for the analysis of patient data. As radiolabeled metabolites of VPM are known to cross the BBB [1], different kinetic modeling parameters obtained in patients and healthy volunteers might be at least partly attributed to different rates of tracer metabolism rather than to differences in cerebral P-gp activity.

References

  1. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, Franssen EJ, Lammertsma AA: Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab. 2007, 27: 424-433. 10.1038/sj.jcbfm.9600349.

    CAS  Article  PubMed  Google Scholar 

  2. Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ: Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol. 2005, 32: 87-93. 10.1016/j.nucmedbio.2004.06.007.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Oliver Langer.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Abrahim, A., Luurtsema, G., Bauer, M. et al. Metabolism of (R)-[11C]verapamil in epilepsy patients. BMC Pharmacol 7, A23 (2007). https://doi.org/10.1186/1471-2210-7-S2-A23

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1471-2210-7-S2-A23

Keywords

  • Positron Emission Tomography
  • Healthy Volunteer
  • Kinetic Modeling
  • Verapamil
  • Antiepileptic Drug